查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
細胞和基因治療製造QC（品管）：歐洲市場分析和預測（2023-2033）
市場調查報告書
商品編碼
1432385

細胞和基因治療製造QC（品管）：歐洲市場分析和預測（2023-2033）

Europe Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 116 Pages | 商品交期: 1-5個工作天內

價格

歐洲細胞和基因治療製造QC（品管）市場規模預計將從2023年的5.343億美元成長到2033年的25.456億美元，預測期內複合年成長率為16.90%。

歐洲細胞和基因治療製造 QC（品管）市場：簡介

主要市場統計數據
預測期 2023-2033
2023年評估 5.343 億美元
2033年預測 25.456 億美元
複合年成長率 16.9%

由於核准的治療方法數量不斷增加以及基礎設施擴建的需求，歐洲細胞和基因療法製造 QC（品管）市場預計將擴大。此外，細胞和基因療法針對的多種疾病需要廣泛的製造和品質控制流程，從而促進市場成長。

由於多種因素，歐洲細胞和基因治療製造品質控制市場正在經歷顯著成長。隨著細胞和基因療法擴大用於治療各種疾病，對嚴格的品管措施的需求越來越大，以確保這些先進療法的安全性、有效性和一致性。歐洲監管機構致力於維持高製造標準，進一步支持市場擴張。此外，分析技術和自動化的進步也增強了品質控制流程並促進高效、可靠的製造。此外，學術機構、生物製藥公司和受託製造廠商(CMO) 之間的合作正在促進創新品質控制解決方案的開發。隨著歐洲繼續在細胞和基因治療領域發揮主導作用，QC 市場有望持續成長和創新。

本報告調查了歐洲細胞和基因治療製造 QC（品管）市場，並提供了市場概況、對市場成長的各種影響因素的分析、法律制度、市場規模趨勢和預測、各種分類，並總結了詳細的分析。主要國家和主要企業的分析。

市場分類

細分 1：依治療類型

  • 細胞療法
  • 基因治療

細分 2：依產品分類

  • 產品
  • 服務

細分 3：按流程

  • 原料準備
  • 上游工程
  • 下游工藝
  • 包裝

細分4：按用途

  • 安全測試
  • 效力測試
  • 身份測試
  • 穩定性/遺傳保真度測試
  • 其他

細分 5：依技術分類

  • 聚合酵素鏈鎖反應(PCR)
  • 流式細胞技術
  • 鱟變形細胞裂解物 (LAL)
  • 酵素結合免疫吸附檢測法(ELISA)
  • 層析法
  • 質譜
  • 西方印漬術
  • 下一代定序（NGS）
  • 電泳
  • 其他技術

細分 6：按國家/地區分類

  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 其他

主要參與企業：

  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Lonza.
  • Sartorius AG

目錄

執行摘要

第1章 市場

  • 產品定義
  • 市場範圍
  • 調查方法
  • 市場概況
    • 全球市場情景
    • 市場足跡和成長潛力
    • 未來性
    • COVID-19 對市場的影響

第2章細胞和基因治療製造QC（品管）市場：產業分析

  • 法律規範

第3章 歐洲

  • 概述
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 其他地區
    • 按產品類別分類的市場
    • 按治療類型分類的市場
    • 按流程分類市場
    • 市場由技術決定
    • 按應用分類的市場

第4章 公司簡介

  • 製造商
  • 服務
Product Code: BHP1897SS

The Europe Cell and Gene Therapy Manufacturing QC Market Expected to Reach $2,545.6 Million by 2033

Introduction to Europe Cell and Gene Therapy Manufacturing QC Market

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$534.3 Million
2033 Forecast$2,545.6 Million
CAGR16.9%

The Europe cell and gene therapy manufacturing Quality Control (QC) market is expected to reach $2,545.6 million by 2033 from $534.3 million in 2023 at a CAGR of 16.90% during the forecast period 2023-2033. The cell and gene therapy manufacturing quality control (QC) market is projected to grow due to the rising number of approved therapies and the need for expanded infrastructure. Furthermore, the broader range of medical conditions targeted by cell and gene therapies necessitates large-scale manufacturing and QC processes, contributing to market growth.

Market Introduction

The cell and gene therapy manufacturing Quality Control (QC) market in Europe is experiencing notable growth driven by several factors. With the increasing adoption of cell and gene therapies for treating various diseases, there's a rising demand for stringent quality control measures to ensure the safety, efficacy, and consistency of these advanced therapies. European regulatory bodies' emphasis on maintaining high manufacturing standards further propels market expansion. Additionally, advancements in analytical technologies and automation are enhancing QC processes, facilitating efficient and reliable manufacturing. Furthermore, collaborations between academic institutions, biopharmaceutical companies, and contract manufacturing organizations (CMOs) contribute to the development of innovative QC solutions. As Europe continues to play a leading role in the cell and gene therapy landscape, the QC market is poised for continued growth and innovation.

Market Segmentation

Segmentation 1: by Therapy Type

  • Cell Therapy
  • Gene Therapy

Segmentation 2: by Offering

  • Products
  • Services

Segmentation 3: by Process

  • Raw Material Preparation
  • Upstream Processing
  • Downstream Processing
  • Packaging

Segmentation 4: by Application

  • Safety Testing
  • Potency Testing
  • Identity Testing
  • Stability and Genetic Fidelity Testing
  • Others

Segmentation 5: by Technology

  • Polymerase Chain Reaction (PCR)
  • Flow Cytometry
  • Limulus Amebocyte Lysate (LAL)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Chromatography
  • Mass Spectrometry
  • Western Blotting
  • Next-Generation Sequencing (NGS)
  • Electrophoresis
  • Other Technologies

Segmentation 6: by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe cell and gene therapy manufacturing QC market (by offering) has been segmented into products and services. Moreover, the study provides the reader with a detailed understanding of the different applications of cell and gene therapy manufacturing QC in raw material preparation, upstream processing, downstream processing, and packaging.

Growth/Marketing Strategy: Cell and gene therapy manufacturing QC is being used for raw material preparation, upstream processing, downstream processing, and packaging. Various companies are providing products and services to aid in the manufacturing and QC of various cell and gene therapies, which is also the key strategy for market players to excel in the current Europe cell and gene therapy manufacturing QC market.

Competitive Strategy: Key players in the Europe cell and gene therapy manufacturing QC market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe cell and gene therapy manufacturing QC market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Lonza.
  • Sartorius AG

Table of Contents

Executive Summary

1 Markets

  • 1.1 Product Definition
    • 1.1.1 Product Definition
    • 1.1.2 Inclusion and Exclusion Criteria
  • 1.2 Market Scope
    • 1.2.1 Key Questions Answered in the Report
  • 1.3 Research Methodology
    • 1.3.1 Cell and Gene Therapy Manufacturing QC Market
    • 1.3.2 Data Sources
      • 1.3.2.1 Primary Data Sources
      • 1.3.2.2 Secondary Data Sources
    • 1.3.3 Market Estimation Model
    • 1.3.4 Criteria for Company Profiling
  • 1.4 Market Overview
    • 1.4.1 Global Market Scenario
      • 1.4.1.1 Realistic Growth Scenario
      • 1.4.1.2 Optimistic Scenario
      • 1.4.1.3 Pessimistic Scenario
    • 1.4.2 Market Footprint and Growth Potential
    • 1.4.3 Future Potential
    • 1.4.4 COVID-19 Impact on Market
      • 1.4.4.1 Impact on Research and Clinical Operations
      • 1.4.4.2 COVID-19 Impact: Current Scenario of the Market
      • 1.4.4.3 Pre- and Post-COVID-19 Impact Assessment
        • 1.4.4.3.1 Pre-COVID-19 Phase
        • 1.4.4.3.2 Post-COVID-19 Phase

2 Cell and Gene Therapy Manufacturing QC Market: Industry Analysis

  • 2.1 Regulatory Framework
    • 2.1.1 Chemistry, Manufacturing, and Control (CMC) Requirements by the Food and Drug Administration (FDA)
      • 2.1.1.1 Product Testing
      • 2.1.1.2 Microbial Testing
      • 2.1.1.3 Identity
      • 2.1.1.4 Purity
      • 2.1.1.5 Potency
      • 2.1.1.6 Viability
      • 2.1.1.7 Cell Number or Dose
    • 2.1.2 Quality Aspects of Cell and Gene Therapy Products by the European Medicines Agency (EMA)
      • 2.1.2.1 Characterization
      • 2.1.2.2 Identity Testing
      • 2.1.2.3 Purity Testing
    • 2.1.3 Current Good Manufacturing Practice (CGMP) Regulations
      • 2.1.3.1 Europe
    • 2.1.4 Regulatory Framework: Cell and Gene Therapy Manufacturing QC Market

3 Europe

  • 3.1 Overview
  • 3.2 Europe
    • 3.2.1 Europe Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.2.2 Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.2.3 Europe Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.2.4 Europe Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.2.5 Europe Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.3 U.K.
    • 3.3.1 U.K. Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.3.2 U.K. Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.3.3 U.K. Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.3.4 U.K. Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.3.5 U.K. Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.4 Germany
    • 3.4.1 Germany Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.4.2 Germany Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.4.3 Germany Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.4.4 Germany Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.4.5 Germany Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.5 France
    • 3.5.1 France Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.5.2 France Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.5.3 France Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.5.4 France Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.5.5 France Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.6 Italy
    • 3.6.1 Italy Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.6.2 Italy Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.6.3 Italy Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.6.4 Italy Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.6.5 Italy Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.7 Spain
    • 3.7.1 Spain Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.7.2 Spain Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.7.3 Spain Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.7.4 Spain Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.7.5 Spain Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.8 Rest-of-Europe
    • 3.8.1 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.8.2 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.8.3 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.8.4 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.8.5 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Application)

4 Company Profiles

  • 4.1 Overview
  • 4.2 Manufacturers
    • 4.2.1 bioMerieux SA
      • 4.2.1.1 Company Overview
      • 4.2.1.2 Role of bioMerieux SA in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.1.3 Key Competitors
      • 4.2.1.4 Financials
      • 4.2.1.5 Analyst Perspective
    • 4.2.2 F. Hoffmann-La Roche Ltd
      • 4.2.2.1 Company Overview
      • 4.2.2.2 Role of F. Hoffmann-La Roche Ltd in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.2.3 Key Competitors
      • 4.2.2.4 Financials
      • 4.2.2.5 Key Insights about the Financial Health of the Company
      • 4.2.2.6 Analyst Perspective
    • 4.2.3 Lonza.
      • 4.2.3.1 Company Overview
      • 4.2.3.2 Role of Lonza. in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.3.3 Key Competitors
      • 4.2.3.4 Financials
      • 4.2.3.5 Analyst Perspective
    • 4.2.4 Miltenyi Biotec B.V. & Co. KG
      • 4.2.4.1 Company Overview
      • 4.2.4.2 Role of Miltenyi Biotec B.V. & Co. KG in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.4.3 Key Competitors
      • 4.2.4.4 Analyst Perspective
    • 4.2.5 Sartorius AG
      • 4.2.5.1 Company Overview
      • 4.2.5.2 Role of Sartorius AG in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.5.3 Key Competitors
      • 4.2.5.4 Financials
      • 4.2.5.5 Analyst Perspective
  • 4.3 Service
    • 4.3.1 Eurofins Scientific
      • 4.3.1.1 Company Overview
      • 4.3.1.2 Role of Eurofins Scientific in the Cell and Gene Therapy Manufacturing QC Market
      • 4.3.1.3 Key Competitors
      • 4.3.1.4 Financials
      • 4.3.1.5 Analyst Perspective
    • 4.3.2 Merck KGaA
      • 4.3.2.1 Company Overview
      • 4.3.2.2 Role of Merck KGaA in the Cell and Gene Therapy Manufacturing QC Market
      • 4.3.2.3 Key Competitors
      • 4.3.2.4 Financials
      • 4.3.2.5 Analyst Perspective

List of Figures

  • Figure 1: Europe Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
  • Figure 2: Europe Cell and Gene Therapy Manufacturing QC Market, Impact Analysis
  • Figure 3: Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), % Share, 2022 and 2033
  • Figure 4: Europe Cell and Gene Therapy Manufacturing QC Market (by Offering), % Share, 2022 and 2033
  • Figure 5: Europe Cell and Gene Therapy Manufacturing QC Market (by Process), % Share, 2022 and 2033
  • Figure 6: Europe Cell and Gene Therapy Manufacturing QC Market (by Technology), % Share, 2022 and 2033
  • Figure 7: Europe Cell and Gene Therapy Manufacturing QC Market (by Application), % Share, 2022 and 2033
  • Figure 8: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
  • Figure 9: Cell and Gene Therapy Manufacturing QC Market: Research Methodology
  • Figure 10: Primary Research Methodology
  • Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 12: Top-Down Approach (Segment-Wise Analysis)
  • Figure 13: Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Realistic Scenario), $Billion, 2022-2033
  • Figure 14: Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Optimistic Scenario), $Billion, 2022-2033
  • Figure 15: Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Pessimistic Scenario), $Billion, 2022-2033
  • Figure 16: Europe Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
  • Figure 17: Impact of COVID-19 on CGT Developmental Activities
  • Figure 18: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
  • Figure 19: Europe Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 20: Europe Cell and Gene Therapy Manufacturing QC Market (by Country), % Share, 2022-2033
  • Figure 21: Europe Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 22: Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 23: Europe Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 24: Europe Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 25: Europe Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 26: U.K. Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 27: U.K. Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 28: U.K. Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 29: U.K. Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 30: U.K. Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 31: U.K. Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 32: Germany Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 33: Germany Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 34: Germany Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 35: Germany Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 36: Germany Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 37: Germany Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 38: France Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 39: France Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 40: France Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 41: France Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 42: France Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 43: France Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 44: Italy Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 45: Italy Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 46: Italy Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 47: Italy Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 48: Italy Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 49: Italy Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 50: Spain Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 51: Spain Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 52: Spain Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 53: Spain Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 54: Spain Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 55: Spain Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 56: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 57: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 58: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 59: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 60: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 61: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 62: Total Number of Companies Profiled
  • Figure 63: bioMerieux SA: Product Portfolio
  • Figure 64: bioMerieux SA: Overall Financials, $Million, 2020-2022
  • Figure 65: bioMerieux SA: Revenue (by Segment), $Million, 2020-2022
  • Figure 66: bioMerieux SA: Revenue (by Region), $Million, 2020-2022
  • Figure 67: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 68: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
  • Figure 69: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
  • Figure 70: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2020-2022
  • Figure 71: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
  • Figure 72: Lonza.: Product Portfolio
  • Figure 73: Lonza.: Overall Financials, $Million, 2020-2022
  • Figure 74: Lonza.: Revenue (by Segment), $Million, 2021and 2022
  • Figure 75: Miltenyi Biotec B.V. & Co. KG: Product Portfolio
  • Figure 76: Sartorius AG: Product Portfolio
  • Figure 77: Sartorius AG: Overall Financials, $Million, 2020-2022
  • Figure 78: Sartorius AG: Revenue (by Segment), $Million, 2020-2022
  • Figure 79: Sartorius AG: Revenue (by Region), $Million, 2020-2022
  • Figure 80: Eurofins Scientific: Product Portfolio
  • Figure 81: Eurofins Scientific.: Overall Financials, $Million, 2020-2022
  • Figure 82: Eurofins Scientific.: Revenue (by Segment), $Million, 2020-2022
  • Figure 83: Eurofins Scientific.: Revenue (by Region), $Million, 2020-2022
  • Figure 84: Merck KGaA: Product Portfolio
  • Figure 85: Merck KGaA: Overall Financials, $Million, 2020-2022
  • Figure 86: Merck KGaA: Revenue (by Segment), $Million, 2020-2022
  • Figure 87: Merck KGaA: Revenue (by Region), $Million, 2020-2022

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Regulatory Scenario: Cell and Gene Therapy Manufacturing QC Market
  • Table 3: Europe Cell and Gene Therapy Manufacturing QC Market Dynamics, Impact Analysis